Larotrectinib (Vitrakvi®) is indicated for patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.
|NCPE Assessment Process||Ongoing|
|Rapid review commissioned||20/11/2019|
|Rapid review completed||13/01/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of larotrectinib compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||20/01/2020|
|Pre-submission consultation with Applicant||20/04/2020|
|Current status||Awaiting HTA submission from Applicant|